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Aim: To examine whether hawthorn (Crataegus Special Extract WS 1442 {CSE}) inhibits progression in heart failure (HF) patients.
Methods: We performed a retrospective analysis of data from the HERB CHF study in which patients with mild to moderate HF were
randomised to either CSE 900 mg or placebo for 6 months. The primary outcome was time to progression of HF (HF death, hospitalisation,
or sustained increase in diuretics) as assessed by log-rank tests and by Cox modelling.
Results: Progression of HF occurred in 46.6% of the CSE and 43.3% of the placebo groups (OR 1.14, 95% CI=0.56, 2.35: p=0.86). Patients
receiving CSE were 3.9 times (95% CI=1.1–13.7: p=0.035) more likely to experience HF progression at baseline. In adjusted analysis, the
risk of having early HF progression in the CSE group increased to 6.4 (95% CI=1.5, 26.5: p=0.011). In patients with LVEF≤35%, those
taking CSE were at significantly greater risk (3.2, 95% CI=1.3, 8.3: p=0.02) than the placebo group.
Conclusions: CSE does not reduce heart failure progression in patients who have HF. CSE appears to increase the early risk of HF
progression.
© 2008 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.Keywords: Hawthorn; Heart failure progression; Crataegus Special Extract WS 1442; Crataegus oxycantha1. Introduction
The pharmacological treatment of heart failure (HF) has
seen tremendous advances in recent years. In appropriate
patients, the addition of β-adrenergic and aldosterone
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doi:10.1016/j.ejheart.2008.04.008have each substantially improved the quality of life and
reduced symptoms of HF, the risk of death and the rate of HF
progression. Nevertheless, even with contemporary evidence
based treatment regimens, progression of HF is inexorable.
As the prevalence of heart failure continues to increase, there
is a pressing need for new agents that could positively affect
HF progression.
Inflammatory signalling and oxidative stress appear to be
involved in transcriptional regulatory pathways that lead to
progression ofHF [1]. Elevated aldosterone levels, which have
been suggested as having a significant role in left ventricular
remodelling, stimulate reactive oxygen species (ROS) in the
myocyte [2]. Thus, inflammatory signalling may be one of the
mechanisms through which activation of the sympathetic
nervous system causes left ventricular remodelling. As the
neurohormonal system is triggered early in HF diseased by Elsevier B.V. All rights reserved.
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theory, reduce the risk of clinical progression.
Crataegus oxycantha, or hawthorn berries, leaves and
flowers and their extracts have been used for cardiac and
circulatory disorders since the first century AD [3]. C.
oxycantha demonstrates numerous properties that may be
beneficial in HF progression, including antioxidant activities
[4–9] and anti-inflammatory effects [10–12]. A recent meta-
analysis of clinical trials concluded that C. oxycantha may
be a safe and effective treatment for HF [13].
Although most previous trials of C. oxycantha have
reported modest improvements in exercise capacity, quality
of life (QOL) and HF-related symptoms [13], none of these
studies have examined the effect of C. oxycantha on HF
progression. Consequently, we performed a secondary data
analysis of a randomised, double-blind, placebo-controlled
trial of Crataegus Special Extract WS1442 in patients with
mild to moderate symptomatic HF (HERB CHF), to examine
the effect of Crataegus Special Extract WS 1442 versus
placebo on clinical measures of HF progression.
2. Methods
We retrospectively analyzed baseline, three and six month
data from 120 HF patients who had completed a six month
randomised, double-blind, placebo-controlled drug trial,
HERB CHF, in which treatment with Crataegus Special
Extract WS 1442 was found to have a neutral effect on
clinical outcomes in patients with New York Heart
Association (NYHA) classes II–IV symptoms [14].
2.1. Study population
Patients aged 18 years and older who had been diagnosed
with HF (NYHA functional classes II–III) for ≥3 months
with a left ventricular ejection fraction (LVEF) ≤40% (by
radionuclide ventriculography, contrast left ventriculography
or echocardiography, assessed during usual clinical care
within the 12 months prior to randomisation) were recruited
from the University of Michigan Health System cardiology
clinics, and from the surrounding community by local
newspaper advertisements. Patients were eligible to partici-
pate if they were receiving indicated standard therapy (if not
contraindicated or intolerant) defined as a diuretic, an ACE
inhibitor or an angiotensin receptor blocker (ARB) and a β-
blocker. Patients with NYHA class III symptoms were also
required to receive spironolactone. Doses of these drugs had
to be stable for ≥3 months, except for diuretics, for which
≥1 month of stability was required.
Patients were ineligible if they had haemodynamically
severe uncorrected primary valvular disease; active myocar-
ditis; hypertrophic cardiomyopathy; restrictive cardiomyo-
pathy; myocardial infarction, stroke, unstable angina,
coronary artery bypass graft surgery, valvular surgery,
cardiac resynchronization therapy or angioplasty ≤3 months
before randomisation. In addition, patients with symptomaticor sustained ventricular tachycardia not controlled by
antiarrhythmic drugs or an implantable cardioverter–defi-
brillator; any condition other than HF that would be expected
to limit exercise (e.g., angina, peripheral vascular disease,
pulmonary disease, arthritis or an orthopaedic problem
severe enough to limit exercise); nursing mothers, pregnant
women and those planning a pregnancy during the study
period, were also excluded. The study was conducted in
accordance with the principles outlined in the Declaration of
Helsinki. The study was approved by the University of
Michigan Medical School Institutional Review Board and
was overseen by an independent Data Safety Monitoring
Board. All participants provided written informed consent.
2.2. Study procedures
Screening occurred at the end of a HF clinic visit. Interested
patients were asked to undertake a 6-minute walk test. Patients
who walked between 150 and 450 m were invited to attend for
a baseline visit within the following two weeks. Written
informed consent was obtained at the beginning of the baseline
visit. If participants were found to be clinically stable and
euvolaemic at the baseline visit, they were asked to perform
another 6-minute walk test. Those who walked between 150
and 450 m were randomised and all others were deemed
ineligible. Eligible patients also had their LVEFs assessed at
the baseline visit by radionuclide ventriculography.
2.3. Intervention
Eligible patients were randomly assigned to receive either
C. oxycantha extract, Crataegus Special Extract WS 1442
(Crataegutt forte®, Willmar Schwabe Pharmaceuticals,
Karlsruhe, Germany), 450 mg twice daily, or a matching
placebo. This dose was chosen based on the manufacturer's
recommendations and on doses used in previous clinical
studies using this extract. Each tablet contained 450 mg dry
extract of C. oxycantha leaves with flowers [4–6.6:1
extraction solvent: ethanol 45%] standardized to 84.3 mg
of oligomeric proanthocyanidins (OPCs). The entire study
was conducted using a single batch of Crataegus Special
Extract WS 1442 to optimize product consistency. Content
of OPCs in the study medication were independently verified
using appropriate high performance liquid chromatography
methods (Integrated Biomolecule; Tucson, AZ). The OPC
content at the end of the study was 84.06 mg/tablet. Placebo
tablets contained lactose, and were coloured to match the
placebo tablets. Participants were told to take the study
medication twice per day with water and to bring all unused
tablets to each study visit. Patients were seen at the study
clinic three months and six months after the baseline visit.
2.4. Statistical analysis
Baseline characteristics are reported by treatment group
using means and standard deviations (SD) for continuous
Table 1
Socio-demographic and clinical characteristics of the study population by
treatment group
Characteristics Placebo, (n=60) Hawthorn, (n=60)
n (%) or mean
(±SD)
n (%) or mean
(±SD)
Sex
Men 44 (73) 46 (77)
Women 16 (27) 14 (23)
Age 57.8 (±9.0) 54.4 (±12.6)
Race
White 50 (83) 45 (75)
Blood pressure, mm Hg
Systolic 113 (±19) 109 (±15)
Diastolic 66 (±10) 66±10
Heart rate, bpm 71±11 68±11
NYHA class
II 33 (55) 30 (50)
III 27 (45) 30 (50)
LVEF, % 34.8 (±14.5) 36.2 (±15.1)
LVEF ≤40% 44 (73) 38 (63)
Six-minute walk test, m 374.0 (±52.4) 358.2 (±59.2)
Peak oxygen consumption,
mL\kg\min
14.6 (±3.8) 14.7 (±3.5)
Medications
ACE inhibitor 46 (77) 48 (80)
ARB 11 (18) 9 (15)
ACE inhibitor or ARB 57 (95) 57 (95)
Beta blocker 52 (87) 54 (90)
Digoxin 49 (82) 47 (78)
Loop diuretic 57 (95) 55 (92)
Spironolactone 39 (65) 39 (65)
Thiazide diuretic 10 (17) 11 (18)
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variables. The primary outcome for this analysis, progression
of HF, was defined as (1) death due to HF, (2) hospitalisation
due to HF, or (3) sustained increase in diuretic dose for HF.
An increase in diuretic dose was defined as an increase of at
least 50% from baseline at either the three month or six
month visit. The three parts of the primary endpoint were
considered in hierarchical order, where HF death took
precedence over HF hospitalisation and HF hospitalisation
had precedence over increased diuretic dose. Consequently,
patients with more than one endpoint were only counted
once.
Our primary outcome, proportion of patients with clinical
progression of HF, was analyzed using Cochran–Mantel–
Haenszel techniques to calculate relative risks (RR) and 95%
confidence intervals (CI). Time to progression by treatment
group was determined by construction of Kaplan–Meier
survival estimates and tested using the log-rank test. To test
for the effect of potentially important prognostic determi-
nants (baseline age, sex, HF aetiology, serum creatinine,
NYHA functional class, serum sodium, peak oxygen
consumption, LVEF, mean blood pressure, Heart Failure
Survival Score [15], β- blocker and ACE inhibitor use as
well as time by treatment interaction) we used Cox
modelling, with backward stepwise regression to determine
the most parsimonious models. An α of ≤0.05 was
considered significant.
With a sample size of 60 per group and a 43% event rate
in the placebo group, we have 84% power to detect a hazard
ratio of 2.0 or greater, assuming alpha=0.05 and two-sided
log-rank test. For the subgroup LVEF of 35% and below,
with a sample size of approximately 34 per group and a 43%
event rate in the placebo group, we have 81% power to detect
a hazard ratio of 2.6 or greater.
3. Results
3.1. Socio-demographic and clinical characteristics
The socio-demographic and clinical characteristics of
participants by treatment group are shown in Table 1. There
were no differences between treatment groups for any
demographic or clinical characteristics. However, despite the
entry requirement of an LVEF≤40% measured during a
clinically-indicated study within the previous 12 months (see
above), the baseline radionuclide ventriculogram performed
after study randomisation detected an LVEFN40% in 38 of
the study participants. Since the baseline assessment of
LVEF occurred after randomisation, we were not able to
exclude these patients.
3.2. Patient flow
Of the 120 patients who were randomised into the HERB
CHF trial, 60 were assigned to placebo and 60 to Crataegus
Special Extract WS 1442. One hundred and eleven patientscompleted all six months of the study. In the placebo group
three patients did not complete the study; one died due to HF,
one had severe pneumonia and one had a United Network for
Organ Sharing (UNOS) status 1 heart transplant. In the
Crataegus Special Extract WS 1442 group six patients did
not complete the study: three patients died, one due to
aplastic anaemia and two due to HF; of the other three
patients: one patient developed Grave's disease; one
developed thyomas and one had a UNOS status 1 heart
transplant.
3.3. Progression of heart failure
Progression of HF occurred in 46.6% (28/60) of Cra-
taegus Special Extract WS1442 patients and 43.3% (26/60)
of placebo patients. This reflects no difference in the
incidence of the primary outcome between the groups
(p=0.86) (Fig. 1). The odds ratio of HF progression was 1.14
(95% CI=0.56, 2.35) for Crataegus Special Extract
WS1442 compared to placebo. Evaluating each component
of the combined endpoint separately, Crataegus Special
Extract WS1442 resulted in nominally more HF deaths
Fig. 1. Heart failure progression endpoints in the Crataegus Special Extract WS 1442 and placebo groups for the 120 patients in the HERB CHF trial.
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11/60 vs. 10.0%, 6/60) but less frequent need for increased
diuretic (25.0%, 15/60 vs. 31.6%, 19/60) compared to
placebo.
The Kaplan–Meier curve for Crataegus Special Extract
WS1442 and placebo (Fig. 2.) showed a crossing pattern that
could indicate changing hazards over time. We consequently
performed a non-proportional Cox regression analysis using
a time by treatment interaction that demonstrated the risk of
HF progression between the two groups changed signifi-
cantly through time (p=0.047). The non-proportional CoxFig. 2. Kaplan–Meier plot of the effect of Crataegus Special Extract WS 1442 vers
Crataegus Special Extract WS 1442 had no effect on the rate of heart failure progmodel demonstrated that patients in the Crataegus Special
Extract WS1442 group were 3.9 times (95% CI=1.1, 13.7:
p=0.035) more likely to experience a HF progression
event at baseline than the placebo group. The hazard ratio
(HR) for the Crataegus Special Extract WS1442 group
decreased through time, so that at six months (182 days)
Crataegus Special Extract WS1442 did not increase
progression (HR=0.63, 95% CI=0.29, 1.47: p=0.72)
compared to the placebo group. In a similar fashion, when
adjusted for baseline NYHA functional class, peak oxygen
consumption, LVEF, Heart Failure Survival Score, and ACEus placebo on progression of heart failure in patients in the HERB CHF trial.
ression (hazard ratio=1.14, (95% CI=0.56, 2.35).
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risk of having a HF progression event at baseline in the
Crataegus Special Extract WS1442 group increased to
HR=6.4 (95% CI=1.5, 26.5: p=0.011) times greater than
the placebo group. At six months (182 days), after
adjustment, Crataegus Special Extract WS1442 again no
longer increased progression (HR=0.41, 95% CI=0.14,
1.18: p=0.64) compared to the placebo group.
We conducted the same analyses on the subgroup of 68
participants with LVEF≤35%. Results in this subgroup of
patients were similar to those observed for the whole group.
Progression of HF occurred in 51.5% (17/33) of Crataegus
Special Extract WS1442 patients and 42.9% (15/35) of
placebo patients. This difference reflects a non-significant
increase in the primary endpoint of 13% (p=0.48) in the
Crataegus Special Extract WS1442 group. The odds ratio
of HF progression was 1.42 (95% CI=0.55, 3.69: p=0.48)
for Crataegus Special Extract WS1442 compared to
placebo.
Kaplan–Meier analysis also demonstrated the possibility
that the risk of having HF events appeared to change through
time between the two groups. A non-proportional Cox
regression analysis indicated that time by treatment interac-
tion was not significant (p=0.13). When adjusted for
baseline peak oxygen consumption, cause of HF, serum
sodium, and ACE inhibitor use, the risk of having a HF
progression event in the Crataegus Special Extract WS1442
group was HR=3.2 (95% CI=1.3, 8.3: p=0.02) times
higher than in the placebo group.
4. Discussion
C. oxycantha in the formulation and dose administered in
this study when added to optimum evidence based therapy
did not decrease the risk of our primary outcome, clinical HF
progression compared to placebo. There were, however,
significantly more HF progression events at baseline in the
Crataegus Special Extract WS1442 group versus the placebo
group. Subgroup analysis of data from patients with
LVEF≤35% demonstrated similar results, although more
ill patients who received Crataegus Special Extract WS1442
were at a significantly increased risk of having a HF
progression event throughout the 6 months of the study and
not just at baseline.
It is unclear why patients who receive Crataegus Special
Extract WS1442 are at greater risk at baseline or if more ill
throughout the entire 6 months of the study for having a HF-
related hospitalisation, death or increased diuretic use. Our
results could well be due to chance, as this study was a
secondary data analysis and had limited power due to the
small sample size. The analysis in sicker patients, with an
even smaller sample size, was even more limited and
vulnerable to chance outcomes. Moreover, as other clinical
trials examining C. oxycantha for HF have not examined the
occurrence of clinical HF events through time, we are unable
to determine if this is a unique conclusion of our study or acommon pattern with C. oxycantha intake in this population.
The Survival and Prognosis: Investigation of Crataegus
Extract WS 1442 in Congestive Heart Failure (SPICE) trial
has recently been completed. The SPICE trial was a
randomised clinical trial in nearly 3000 HF patients with
LVEF≤35%, the primary endpoint was cardiac morbidity,
non-fatal myocardial infarction and hospitalisation due to HF
progression over 24 months [16]. The SPICE trial used
Crataegus Special Extract WS1442 at the same dose as in
our study and enrolled patients with similar baseline
demographic and clinical characteristics [17]. However,
since the SPICE trial has not yet been published, only data
presented orally and in the associated abstract are currently
available, allowing only limited comparisons with our study
data. The SPICE trial reported similar results to our study, in
that there was no significant difference in HF progression
between the active and placebo groups (27.9% vs. 28.9%:
p=NS), although clearly our trial had a higher percentage
of HF progression events (46.6% vs. 43.3%) [16]. Kaplan–
Meier curves have not yet been presented for the SPICE trial,
consequently it is unclear if the relative risk between the
active and placebo groups changed through time, and if there
was an increased risk in the Crataegus Special Extract
WS1442 group at baseline or in sicker patients.
One possible explanation for the increased risk for
progression of HF at baseline in the Crataegus Special
Extract WS1442 group and for patients with LVEF≤35%
(in the adjusted analysis) is the possibility of herb–drug
interactions. As the majority of patients with HF are on
several different drugs, many interactions are theoretically
possible. In particular, the flavonoids in C. oxycantha are
chemically similar to other flavonoids that have demon-
strated P-glycoprotein activity, which may lead to various
drug–flavonoid interactions [18–20]. Only one study has
examined possible interactions between C. oxycantha and a
commonly administered HF medication, digoxin. This study
found that Crataegus Special Extract WS 1442 (450 mg
twice daily) did not significantly alter the pharmacokinetic
parameters of digoxin [21]. Further, several flavonoids in C.
oxycantha such as the vitexin rhamnosides have been
demonstrated to have low oral absorption or undergo
extensive conjugation before reaching the systemic circula-
tion [22–23]. Both the negative study examining potential
interactions with digoxin and the low level absorption of the
main flavonoids present in C. oxycantha diminish the
potential of possible C. oxycantha–drug interactions. It is
possible that constituents other than flavonoids in C.
oxycantha may cause herb–drug interactions, but currently
there is not enough information to determine whether C.
oxycantha–drug interaction led to the increased early risk of
HF progression.
This study had several limitations. As with all secondary
analyses this study was not designed a priori to detect HF
progression events. As such, we did not have a data collection
method in place to monitor changes in HF medications con-
tinuously over the sixmonth study period. Insteadwe collected
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at baseline, three and six months. At three and six months, we
noted if the patient's diuretic dosewas increased from their last
visit. As a consequence we could have included patients who
did not truly have an increased sustained diuretic dose and
missed including patients with sustained increased diuretic
dose. These potential misclassifications, however, should have
been non-differentially spread across both groups, thus keep-
ing the risk relationships between the two groups the same.
Another major limitation of this study is its small sample
size. With 54 events in 120 patients we are able to detect
relatively moderate changes in hazard ratios (2 times or
greater) between the groups but not small differences. This is
even more pronounced in the subgroup analyses of patients
with LVEF of≤35% where we have 32 events in 68 patients.
We suggest that healthcare providers use caution when con-
sidering prescribing C. oxycantha to patients with HF. Patients
already taking C. oxycantha should also be observed closely
for any adverse events that could be temporally related to C.
oxycantha ingestion.Wemake these recommendations because
Crataegus Special Extract WS1442, at a commonly recom-
mended dose, significantly increased the risk for progression of
HF at baseline and in the more clinically compromised patients
with LVEF≤35% in this study. Moreover, Crataegus Special
Extract WS1442 increased risk consistently in more compro-
mised patients with LVEF≤35%.
In summary, Crataegus Special Extract WS 1442 does
not reduce heart failure progression in patients who have
mild to moderate HF. Crataegus Special Extract WS 1442
appears to increase the early risk of heart failure progression.
Acknowledgements
We are grateful for the work of the members of the Data
Safety Monitoring Board (Drs. Gary Chase, Jonathan Sackner
Bernstein, Allen Sedman, Cynthia Long and Shan Wong), and
for the contributions of our study team: Drs. Robert Cody, Todd
Koelling, David Bradley Dyke, Audrey Wu, Ragaven Baliga
(UM Heart Failure and Transplant Management Program);
Brian Nordin (exercise physiology); Dr. Roberta Tankanow
(research pharmacy); E. Mitchell Seymour (laboratory
sciences); Dr. James Corbett (nuclear medicine); Margaret
Ann Murphy (data management); Alexis Zirpoli and Amie
Litzinger (manuscript preparation); Katherine Rice, Patricia
Stimac, Robert Adwere-Boamah, AmyBlume and Fayeannette
Pierce (clinical research assistants); Drs. Sara Warber and
Steven Bolling (U-M Complementary and Alternative Medi-
cine Research Center).Wewould also like to thankDr.Willmar
Schwabe Pharmaceuticals and Dr. Günter Meng for generously
providing the Crataegus Special Extract WS 1442 and match-
ing placebo.
References
[1] Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms
in heart failure. J Am Coll Cardiol 2006;48:A56–66.[2] Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor
inhibition ameliorates the transition to myocardial failure and decreases
oxidative stress and inflammation in mice with chronic pressure
overload. Circulation 2005;111:420–7.
[3] Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr
Med 1996;114:27–9.
[4] Veveris M, Koch E, Chatterjee SS. Crataegus Special Extract WS
1442 improves cardiac function and reduces infarct size in a rat
model of prolonged coronary ischemia and reperfusion. Life Sci
2004;74:1945–55.
[5] Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced
arrhythmias: beneficial effects of an extract of Crataegus oxyacantha
L. Pharm Pharmacol Lett 1993;3:45–8.
[6] Periera da Silva A, Rocha R, Silva CM, Mira L, Duarte MF, Florencio
MH. Antioxidants in medicinal plant extracts. A research study of the
antioxidant capacity of Crataegus, Hamamelis and Hydrastis. Phytother
Res 2000;14:612–6.
[7] Bahorun T, Aumjaud E, Ramphul H, et al. Phenolic constituents and
antioxidant capacities of Crataegus monogyna (Hawthorn) callus
extracts. Nahrung 2003;47:191–8.
[8] Kirakosyan A, Seymour E, Kaufman PB, Warber S, Bolling S, Chang
SC. Antioxidant capacity of polyphenolic extracts from leaves of
Crataegus laevigata and Crataegus monogyna (Hawthorn) subjected
to drought and cold stress. J Agric Food Chem 2003;51:3973–6.
[9] Zhang Z, Chang Q, Zhu M, Huang Y, Ho WKK, Chen ZY.
Characterization of antioxidants present in hawthorn fruits. J Nutr
Biochem 2001;12:144–52.
[10] Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In vitro and in vivo
studies on the cardioprotective action of oligomeric procyanidins in a
Crataegus extract of leaves and blooms. Arzneimittelforschung
1997;47:821–5.
[11] Schwitters B. OPC in Practice. Rome: Alfa Omega Edetrice; 1993.
[12] Masquelier J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. In: Beal JL, Reinhard E, editors. Natural
Products as Medicinal Agents: Plenary Lectures of the International
Research Congress on Medicinal Plant Research, Strasbourg, July
1980. Stuttgart: Hippokrates Verlag; 1981.
[13] Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic
heart failure: meta-analysis of randomized trials. Am J Med
2003;114:665–74.
[14] Aaronson KD. HERB-CHF (Hawthorn Extract Randomized Blinded
ChronicHF Study). Late-breaking and Recent Clinical Trials. 8thAnnual
Scientific Meeting of the Heart Failure Society of America. Toronto,
Ontario, Canada, vol. 10. J Card Fail; 2004. Supp (Abstract 2832).
[15] Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini
DM. Development and prospective validation of a clinical index to
predict survival in ambulatory patients referred for cardiac transplant
evaluation. Circulation 1997;12:2660–7.
[16] Holubarsch CJ, Colucci WS, Meinertz T, GausW, Tendera M. Survival
and prognosis: investigation of Crataegus Extract WS 1442 in
congestive heart failure (SPICE)—rationale, study design and study
protocol. Eur J Heart Fail 2000;2:431–7.
[17] Holubarsch CJ, WS C, Meinertz T, et al. Crataegus extract WS1442
postpones cardiac death in patients with congestive heart failure class
NYHA II–III: a randomized placebo-controlled, double-blind trials in
2681 patients. Late Breaking Clinical Trials-3, Sessions 414–5. New
Orleans, LA: American College of Cardiology; 2007. (Abstract).
[18] Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I.
Pharmacokinetic interaction of digoxin with an herbal extract from
St John's wort (Hypericum perforatum). Clin Pharmacol Ther
1999;66:338–45.
[19] Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a
flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux
in human intestinal Caco-2 cells. J Agric Food Chem 2007;55:7620–5.
[20] Lohner K, Schnabele K, Daniel H, et al. Flavonoids alter P-gp
expression in intestinal epithelial cells in vitro and in vivo. Mol Nutr
Food Res 2007;51:293–300.
593S.M. Zick et al. / European Journal of Heart Failure 10 (2008) 587–593[21] Tankanow R, Tamer HR, Streetman DS, et al. Interaction study
between digoxin and a preparation of hawthorn (Crataegus oxya-
cantha). J Clin Pharmacol 2003;43:637–42.
[22] Liang M, Xu W, Zhang W, et al. Quantitative LC/MS/MS method and
in vivo pharmacokinetic studies of vitexin rhamnoside, a bioactiveconstituent on cardiovascular system from hawthorn. Biomed
Chromatogr 2007;21:422–9.
[23] Zuo Z, Zhang L, Zhou L, Chang Q, Chow M. Intestinal absorption of
hawthorn flavonoids—in vitro, in situ and in vivo correlations. Life Sci
2006;79:2455–62.
